ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion
5,25 EUR
±0,00 %±0,00
24. May, 10:31:31 Uhr,
Berlin
Kommentare 166
Yakuzzi05,
13.04.2022 13:39 Uhr
0
Läuft endlich mal, geil 🤩
Summer.76,
13.04.2022 13:26 Uhr
0
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
https://www.prnewswire.com/news-releases/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader-301524604.html
Summer.76,
29.03.2022 14:36 Uhr
0
Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
https://www.globenewswire.com/news-release/2022/03/29/2411744/35385/en/Antares-Pharma-Announces-FDA-Approval-Of-TLANDO-an-Oral-Treatment-for-Testosterone-Replacement-Therapy.html
Commercial launch expected in 2Q 2022
Summer.76,
03.03.2022 13:33 Uhr
0
Antares Pharma Non-GAAP EPS of $0.02 beats by $0.01, revenue of $48.73M beats by $1.54M
https://seekingalpha.com/news/3808993-antares-pharma-non-gaap-eps-of-0_02-beats-0_01-revenue-of-48_73m-beats-1_54m
Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01.
Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M.
The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate vs. $211.38M consensus.
Summer.76,
03.03.2022 13:24 Uhr
0
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2022/03/03/2396099/35385/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-and-Operating-Results.html
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million
Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share
Full-Year 2021 Adjusted EBITDA of $39.2 Million
2022 Revenue Guidance Range of $200 to $220 Million
Summer.76,
03.02.2022 15:35 Uhr
0
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
https://www.globenewswire.com/news-release/2022/02/03/2378482/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-NDA-Resubmission-for-TLANDO.html
PDUFA target action date set for March 28, 2022
Summer.76,
16.12.2021 8:12 Uhr
0
Antares Pharma Announces Divestiture of Otrexup®
https://www.globenewswire.com/news-release/2021/12/15/2353151/0/en/Antares-Pharma-Announces-Divestiture-of-Otrexup.html
...today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022. ...
Summer.76,
30.11.2021 17:14 Uhr
0
Antares Pharma Granted U.S. Patent #11,185,642 'Injection device with cammed ram assembly'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6129&f=G&l=50&d=PTXT&p=123&S1=20211130&OS=20211130&RS=20211130
Summer.76,
08.11.2021 21:40 Uhr
0
https://finance.yahoo.com/news/lpcn-antares-agreement-nash-fast-131800309.html
Summer.76,
04.11.2021 15:51 Uhr
0
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2021/11/04/2327256/35385/en/Antares-Pharma-Reports-Third-Quarter-2021-Financial-and-Operating-Results.html
Increased Revenue 20% Year-Over-Year to $48.2 Million
Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share
Summer.76,
03.11.2021 7:47 Uhr
0
Antares Pharma Enters Into Credit Agreement For Credit Facilities Of Up To $40 Million
https://last10k.com/sec-filings/atrs/0001016169-21-000034.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=atrs
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | CoinBase (Future ExChange) | +5,67 % | |
2 | APPLE Hauptdiskussion | +8,85 % | |
3 | Jaguar Health für Investierte und Interessierte | +41,33 % | |
4 | GAZPROM Hauptdiskussion | ±0,00 % | |
5 | SUPER MICRO Hauptdiskussion | +2,94 % | |
6 | VW Hauptdiskussion | -2,60 % | |
7 | Cloudflare Registered (A) Hauptdiskussion | -13,95 % | |
8 | MEYER BURGER Hauptdiskussion | +11,61 % | |
9 | Trading- und Aktien-Chat | ||
10 | für alle, die es ehrlich meinen beim Traden. | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | CoinBase (Future ExChange) | +5,86 % | |
2 | APPLE Hauptdiskussion | +8,85 % | |
3 | Jaguar Health für Investierte und Interessierte | +39,73 % | |
4 | GAZPROM Hauptdiskussion | ±0,00 % | |
5 | SUPER MICRO Hauptdiskussion | +2,94 % | |
6 | VW Hauptdiskussion | -2,60 % | |
7 | Cloudflare Registered (A) Hauptdiskussion | -13,95 % | |
8 | MEYER BURGER Hauptdiskussion | +11,61 % | |
9 | PAYPAL Hauptdiskussion | +1,06 % | |
10 | Nantkwest / Immunitybio -> IBRX | +11,24 % | Alle Diskussionen |